Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
GLOBE SCIENTIFIC, LLC

Download Mobile App





SARS-CoV-2 Blood Biomarker Identifies Infected Patients Most at Risk of Dying of COVID-19

By LabMedica International staff writers
Posted on 29 Nov 2021

A statistical model developed by researchers uses a blood biomarker of SARS-CoV-2 to identify infected patients who are most at risk of dying of COVID-19. More...

The study by researchers at the Université de Montréal (Montréal, Canada) found that the amount of a SARS-CoV-2 genetic material - viral RNA - in the blood is a reliable indicator in detecting which patients will die of the disease. Despite advances in the management of COVID-19, doctors have found it hard to identify patients most at risk of dying of the disease and so be able to offer them new treatments. Several biomarkers have been identified in other studies, but juggling the profusion of parameters is not possible in a clinical setting and hinders doctors’ ability to make quick medical decisions.

Using blood samples collected from 279 patients during their hospitalization for COVID-19, ranging in degrees of severity from moderate to critical, the research team measured amounts of inflammatory proteins, looking for any that stood out. At the same time, the researchers also measured the amounts of viral RNA and the levels of antibodies targeting the virus. Samples were collected 11 days after the onset of symptoms and patients were monitored for a minimum of 60 days after that. The goal was to test the hypothesis that immunological indicators were associated with increased mortality.

“Among all of the biomarkers we evaluated, we showed that the amount of viral RNA in the blood was directly associated with mortality and provided the best predictive response, once our model was adjusted for the age and sex of the patient,” said Elsa Brunet-Ratnasingham, a doctoral student and co-first author of the study. “We even found that including additional biomarkers did not improve predictive quality.”

“In our study, we were able to determine which biomarkers are predictors of mortality in the 60 days following the onset of symptoms,” said Dr. Daniel Kaufmann, Université de Montréal medical professor who led the research team. “Thanks to our data, we have successfully developed and validated a statistical model based on one blood biomarker,” viral RNA.

Related Links:
Université de Montréal 


Gold Member
Universal Transport Solution
Puritan®UniTranz-RT
Serological Pipet Controller
PIPETBOY GENIUS
New
Varicella Zoster Virus Assay
LIAISON VZV Assay Panel (IgG HT, IgM)
New
Host Response Immunoassay Test
MeMed BV
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: A simple blood test could replace surgical biopsies for early detecion of heart transplant rejection (Photo courtesy of Shutterstock)

Blood Test Detects Organ Rejection in Heart Transplant Patients

Following a heart transplant, patients are required to undergo surgical biopsies so that physicians can assess the possibility of organ rejection. Rejection happens when the recipient’s immune system identifies... Read more

Pathology

view channel
These images illustrate how precision oncology Organ Chips recapitulate individual patients’ responses to chemotherapy (Photo courtesy of Wyss Institute at Harvard University)

Cancer Chip Accurately Predicts Patient-Specific Chemotherapy Response

Esophageal adenocarcinoma (EAC), one of the two primary types of esophageal cancer, ranks as the sixth leading cause of cancer-related deaths worldwide and currently lacks effective targeted therapies.... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.